Evidence map›Paper›PMID 37868720›Full record

ArticleRegenerative therapy2023

Ascorbic acid enhances the cold preservation period of human adipose tissue-derived mesenchymal stromal cells.

Tamaki Wada, Taichi Takenawa, Natsuki Komori, Masuhiro Nishimura, Yasutaka Fujita, Osamu Sawamoto

Open access · goldAbstract read
In one paragraph

Article in Regenerative therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tamaki WadaResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Taichi TakenawaResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Natsuki KomoriResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Masuhiro NishimuraResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Yasutaka FujitaResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Osamu SawamotoResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Japan.
Otsuka (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: We previously developed 3% trehalose-added lactated Ringer's solution (LR-3T) and 3% trehalose- and 5% dextran-40-added lactated Ringer's solution (LR-3T-5D), which can be used to preserve adipose-derived mesenchymal stem cells (hADSCs) for 24 h at 5 and 25 °C. However, it is necessary to further extend the storage duration of cells to expand transportation zones and ensure time for quality control testing of final cell products. Therefore, we attempted to prolong the preservation duration of hADSCs by adding supplements to LR-3T-5D. We focused on ascorbic acid as an antioxidant because it is widely clinically as a nutrient. Methods: We added the antioxidant ascorbic acid to LR-3T-5D and evaluated the viability, colony formation rate, proliferative capacity, and surface markers of hADSCs before and after preservation at 5 °C. Results: Analysis of the concentration of ascorbic acid added to LR-3T-5D indicated that 1000 mg/L was the optimal concentration for maintaining the viability of hADSCs after 72 h of cold preservation. No changes were observed in the expression of specific cell surface markers or in the potential of hADSCs to differentiate into adipocytes, osteoblasts, or chondrocytes before and after cold preservation. Discussion: These results suggest that cold preservation of hADSCs in LR-3T-5D supplemented with ascorbic acid helps maintain the quality of cells for use in cell therapy.

Indexed as

Ascorbic acidCold preservationHuman adipose-derived mesenchymal stromal cells

Identifiers

PMID37868720
PMCPMC10584694
OpenAlexW4382359333

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.